目的 探討天舒膠囊聯(lián)合舒馬普坦治療偏頭痛的臨床療效。方法 選取2018年3月-2019年3月在平頂山市第二人民醫(yī)院進行治療的88例偏頭痛患者，根據(jù)用藥的差別分為對照組（44例）和治療組（44例）。對照組口服琥珀酸舒馬普坦片，25 mg/次，1次/d；治療組在對照組基礎上口服天舒膠囊，1.36 g/次，3次/d。兩組均經(jīng)過4周治療后進行效果比較。觀察兩組的臨床療效，比較兩組治療前后相關評分、血清學指標的變化情況。結果 經(jīng)過治療，對照組有效率為81.82%，顯著低于治療組97.73%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組頭痛程度、頭痛發(fā)作次數(shù)、頭痛持續(xù)時間和頭痛伴隨癥狀等評分均較治療前顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療后，治療組這些癥候評分明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。兩組PSQI評分、GQOLI-74評分、VAS評分均較治療前顯著改善，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療后，治療組這些相關量表評分的改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。兩組血清環(huán)氧化酶-2（COX-2）、神經(jīng)元特異性烯醇酶（S-NSE）、基質(zhì)金屬蛋白酶-9（MMP-9）、血栓素B2（TXB2）、5-羥色胺（5-HT）水平均較治療前顯著下降，而β-內(nèi)啡肽（β-EP）水平均顯著升高，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；治療后，治療組這些血清學指標改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 天舒膠囊聯(lián)合舒馬普坦治療偏頭痛具有較好的臨床療效，可有效改善患者臨床癥狀，改善機體相關血清學指標水平，提高患者睡眠及生活質(zhì)量，具有一定的臨床推廣應用價值。

Objective To explore the clinical effect of Tianshu Capsules combined with sumatriptan in treatment of migraine. Methods Patients (88 cases) with migraine in Pingdingshan Second People's Hospital from March 2018 to March 2019 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were po administered with Sumatriptan Succinate Tablets, 25 mg/time, once daily. Patients in the treatment group were po administered with Tianshu Capsules on the treatment group, 1.36 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scores and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.82% and 97.73% respectively, and there were differences between two groups (P<0.05). After treatment, scores of headache severity, headache attack times, headache duration and headache accompanying symptoms in both groups were significantly lower than those before treatment, and there were differences in the same group (P<0.05). After treatment, these symptom scores were significantly lower in the treatment group than those in the control group, and there were differences between two groups (P<0.05). After treatment, PSQI score, GQOLI-74 score, and VAS score were significantly improved compared with those before treatment, and there were differences in the same group (P<0.05). After treatment, the improvement of these scales in the treatment group were better than those in the control group, and there were differences between two groups (P<0.05). After treatment, COX-2, S-NSE, MMP-9, TXB2, and 5-HT in two groups were significantly decreased, but β-EP was significantly increased, and there were differences in the same group (P<0.05). After treatment, these serological indicators improved better in the treatment group than those in the control group, and there were differences between two groups (P<0.05). Conclusion Tianshu Capsules combined with sumatriptan has significant effect in treatment of migraine, and can effectively improve the clinical symptoms, and also can improve the level of related serological indicators, and improve the sleep quality and life of patients.

R971